- Home
- SQFT vs APRE Comparison
SQFT vs APRE Comparison
Compare SQFT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- APRE
- Stock Information
- Founded
- SQFT 1999
- APRE 2006
- Country
- SQFT United States
- APRE United States
- Employees
- SQFT N/A
- APRE N/A
- Industry
- SQFT Real Estate Investment Trusts
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SQFT Real Estate
- APRE Health Care
- Exchange
- SQFT Nasdaq
- APRE Nasdaq
- Market Cap
- SQFT 7.7M
- APRE 8.3M
- IPO Year
- SQFT 2020
- APRE 2019
- Fundamental
- Price
- SQFT $6.16
- APRE $1.45
- Analyst Decision
- SQFT
- APRE Strong Buy
- Analyst Count
- SQFT 0
- APRE 1
- Target Price
- SQFT N/A
- APRE $20.00
- AVG Volume (30 Days)
- SQFT 43.1K
- APRE 142.7K
- Earning Date
- SQFT 11-11-2025
- APRE 11-07-2025
- Dividend Yield
- SQFT N/A
- APRE N/A
- EPS Growth
- SQFT N/A
- APRE N/A
- EPS
- SQFT N/A
- APRE N/A
- Revenue
- SQFT $18,052,597.00
- APRE $841,012.00
- Revenue This Year
- SQFT $23.63
- APRE N/A
- Revenue Next Year
- SQFT N/A
- APRE N/A
- P/E Ratio
- SQFT N/A
- APRE N/A
- Revenue Growth
- SQFT N/A
- APRE N/A
- 52 Week Low
- SQFT $4.19
- APRE $1.31
- 52 Week High
- SQFT $23.00
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- SQFT 56.07
- APRE 46.64
- Support Level
- SQFT $5.68
- APRE $1.31
- Resistance Level
- SQFT $6.34
- APRE $1.69
- Average True Range (ATR)
- SQFT 0.35
- APRE 0.10
- MACD
- SQFT 0.04
- APRE -0.01
- Stochastic Oscillator
- SQFT 81.08
- APRE 36.84
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.